Latest Psychedelic Therapies News

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

Entropy Neurodynamics has successfully dosed all six participants in the first cohort of its Phase 2 trial for TRP-8803, an intravenous psilocin therapy targeting Binge Eating Disorder. The study demonstrated controlled psychedelic responses, setting the stage for a Data and Safety Monitoring Board review and topline results expected in July 2026.

The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.

Emyria has launched its first Empax clinic in Victoria on schedule, establishing a new clinical hub with trained staff and dual reimbursement pathways to support growth.

Entropy Neurodynamics has bolstered its intellectual property portfolio with a new US provisional patent application for TRP-8803, following compelling Phase 2a data showing a 75% response rate in treatment-resistant IBS patients.

Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.

Emyria has unveiled the Empax Global Partnership Program, a high-margin clinical delivery platform targeting international drug sponsors amid growing demand for psychedelic-assisted mental health treatments.

Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.

Vitura Health has appointed Justin James as its new CEO, bringing a wealth of healthcare leadership and a proven track record in specialty therapies to accelerate the company’s transformation.

Emyria Limited has launched a targeted recruitment campaign in New South Wales to establish its fourth state-based clinical operation, aiming to tap into Australia's largest mental health market amid rising psychological injury claims.

Entropy Neurodynamics has received a $1.73 million R&D tax incentive refund from the Australian Government, reinforcing its clinical development of an intravenous psilocin treatment for neuropsychiatric disorders.